Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID)

Corporacion Parc Tauli

Status: Completed

Conditions: Covid-19

Treatments: Diagnostic Test: ELISA and Rapid test to detect antibodies against COVID-19

Study type: Observational

Funder types: Other

Identifiers

NCT04490837

2020/587

Details and patient eligibility

About

Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices. This test will be developed using innovative technology developed at the Parc Taulí University Hospital, which increases the immunogenicity of SARS-CoV-2 differential antigens. The increased immunogenicity of these antigens will allow to detect, with a high sensitivity and specificity, the antibodies in the serum of patients infected with SARS-CoV-2. This test will serve to confirm dubious results as well as reduce false negatives from the PCR test, which will ultimately help reduce transmission of the infection.

Enrollment: 3,500 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Professional from Parc Taulí University Hospital
• Patients with clinical, radiological and/or PCR COVID-19 positive

Exclusion criteria

• Patients or professionals who do not sign informed consent

Trial design

3,500 participants in 3 patient groups

COVID-19 positive

Description:

Patients with clinical, radiological and/or PCR positive for COVID-19 infection

Treatment:

Diagnostic Test: ELISA and Rapid test to detect antibodies against COVID-19

Normal

Description:

Normal human serum from blood donnors before COVID-19 pandemia

Treatment:

Diagnostic Test: ELISA and Rapid test to detect antibodies against COVID-19

Pathological controls

Description:

Patients with other positive virological serologies

Treatment:

Diagnostic Test: ELISA and Rapid test to detect antibodies against COVID-19